Kodiak Sciences Inc Common Stock (KOD) Financials
Key financial figures for Kodiak Sciences Inc Common Stock (Q3 2026).
Kodiak ended Q3 2026 with $88.7M of cash against a $66.2M quarterly net loss, then raised $69M through its at-the-market facility after quarter-end while guiding to a December KSI-101 readout and a Zenkuda BLA by year end. Net loss was $66.2M, or $1.05 per share, versus $61.5M, or $1.16 per share, in Q3 2025. The per-share loss narrowed even though the dollar loss grew because the weighted-average share count rose to about 63.0M from about 52.9M. R&D expense was $58.3M versus $50.5M a year earlier (about +15.5%, calculated), which the company attributes to clinical activity in the PEAK/PINNACLE and ALTO studies and manufacturing to support its Phase 3 programs. G&A expense was $8.8M versus $11.9M (about -25.9%, calculated). On the outlook: The press release carried no financial guidance. It stated that current cash and cash equivalents are expected to support current and planned operations into 2027, a Zenkuda multi-indication BLA submission planned for the fourth quarter of 2026, first Phase 3 KSI-101 (PEAK) topline results expected in December 2026 with a BLA for KSI-101 planned for the second quarter of 2027 if successful, and topline data from the second pivotal KSI-101 cohort expected in the second quarter of 2027. Figures are for Q3 2026, as Kodiak Sciences Inc. reported them.
- Revenue
- $0
- Net Income
- -$66M
- EPS
- $-1.05
- Total Assets
- $209M
- Operating Cash Flow
- -$44M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $0 | -$66M | -$1.05 | -$46M | |
| Q2 FY2026 | $0 | -$66M | -$1.05 | -$47M | |
| Q1 FY2026 | $0 | -$58M | -$0.94 | -$41M | |
| Q4 FY2025 | $0 | -$57M | -$1.04 | -$39M | |
| Q3 FY2025 | $0 | -$61M | -$1.16 | -$33M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$230M | -$4.32 | -$137M | |
| FY2024 | $0 | -$176M | -$3.35 | -$118M | |
| FY2023 | $0 | -$260M | -$4.97 | -$196M |
Frequently asked questions
What was Kodiak Sciences Inc.'s revenue last quarter?
Kodiak Sciences Inc. reported revenue of $0.00 for Q3 FY2026.
Is Kodiak Sciences Inc. profitable?
Not in its most recent reported period. Kodiak Sciences Inc. reported a net loss of $66.2 million for Q3 FY2026.
How much free cash flow did Kodiak Sciences Inc. generate?
Kodiak Sciences Inc. generated free cash flow of -$45.8 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Kodiak Sciences Inc Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.